Gordon Camp (Parkinson #39;s Disease) Stem Cell Therapy
New Project 46From:OmarGonzalezMDViews:0 0ratingsTime:06:29More inScience Technology

Original post:
Gordon Camp (Parkinson's Disease) Stem Cell Therapy - Video

Recommendation and review posted by Bethany Smith

"Labrum Tear is now Being Treated With Cell Therapy at the Center for Regenerative Medicine Using," according to Dr. Farshchian MD, medical director for the center for regenerative medicine.

(PRWEB) December 11, 2012

Sports injuries need an adequate blood supply and cellular migration. Platelet-derived growth factors are critically involved in this process. These cells allow the body to take advantage of the normal healing pathways at a greatly accelerated rate. During the healing process, the body rushes many cells and cell-types to the injected area in order to accelerate the healing process. These cells perform many functions, including release of growth factors (GF) into the diseased or arthritic and injured sites.

The labrum is a fibrocartilaginous rim which attaches to the acetabulum cavity (This is where the hip joint is located). Its job is to protect the femur (or the hip bone) and decrease any unevenness in its surface. The labrum is important since it decreases stresses between the joint surfaces, by producing a "sealing effect". It acts as a bumper which deepens the joint socket and helps keep the head of femur in place.

The vascularity or blood flow is minimal which is not a good thing at all, this factor makes self healing hard to come by.

Although not very specific the FABRE test (see picture) could be positive in presence of a tear. Here the examiner is anchoring patient's ankle against the opposite knee and pressing on the knee reproducing pain and tenderness in the anterior hip (medical lingo: front).

MRI with contrast is a more specific test allowing the physician to actually visualize the tear.

The condition is painful and annoying since it interferes with activities, This entity may be a risk factor future arthritis and problems to follow. This condition is not common at all but the several times that I have seen it it has involved aggressive physical activity such as jumping on a trampoline or sports injury.

U.S.A. based physician, Dr. Farshchian is a medical author, humanitarian, and active republican member. He is best known for coining the term orthopedic regenerative medicine. Dr. Farshchian is recognized as a leading authority in the new clinical science of regenerative medicine. He is also a Television personality currently hosting "The Arthritis Show".

The Center for Regenerative Medicine in Miami, Florida concentrates on helping arthritic and injured people to get back to a functional level of life and their activities using non-surgical techniques and Orthopedic medicine. The center's expertise is in treatment of conditions of spine, knees , shoulders , and other cartilage damages. They have developed non-surgical and rehabilitation techniques focused on treatment and management of joint pain. Their team includes health professionals organized around a central theme. their website is http://www.arthritisusa.net

More here:
Dr. Farshchian: Labrum Tear is Now Being Treated With Cell Therapy at the Center for Regenerative Medicine Using

Recommendation and review posted by Bethany Smith

Autologous cell therapy is now being used to help with neck pain at The Center for Regenerative Medicine, according to Dr. Farshchian, the medical director for the center for Regenerative medicine.

(PRWEB) December 10, 2012

All the interconnected structures that give your neck its incredible range of motion are subject to the wear-and-tear damage of arthritis and the over extension injuries of whiplash. Neck pain may result from abnormalities in the soft tissues - the muscles, ligaments, and nerves - as well as in bones and joints of the spine. The most common causes of neck pain are soft tissue abnormalities due to injury or prolonged wear and tear. In rare cases, infection or tumors may cause neck pain. In some people, neck problems may be the source of pain in the upper back, shoulders or arms.

Degenerative diseases that cause neck pain include osteoarthritis and rheumatoid arthritis. Osteoarthritis usually occurs in older people as a result of wear of the joints between the bones in the neck. Rheumatoid arthritis can cause destruction of the joints of the neck. Both of these major types of arthritis can cause stiffness and pain.

Cervical disk degeneration also can cause neck pain. The disk acts as a shock absorber between the bones in the neck. In cervical disk degeneration (typically age 40 onwards), the normal gelatin-like center of the disk degenerates and the space between the vertebrae narrows. As the disk space narrows, added stress is applied to the joints of the spine causing further wear and degenerative disease.

The cervical disk may also protrude and cause pressure on the spinal cord or nerve roots when the rim of the disk weakens. This is known as a herniated cervical disk. Because the neck is so flexible and because it supports the head, it is extremely vulnerable to injury. Motor vehicle or diving accidents, contact sports, and falls may result in neck injury. The regular use of safety belts in motor vehicles can help to prevent or minimize injury. A "rear end" automobile collision may result in hyper extension, a backward motion of the neck beyond normal limits, or hyperflexion, a forward motion of the neck beyond normal limits. Most common injuries are to the soft tissues, i.e., muscles and ligaments. Severe injury with fracture or dislocation of the neck may damage the spinal cord and cause paralysis.

Sports injuries need an adequate blood supply and cellular migration. Platelet-derived growth factors are critically involved in this process. These cells allow the body to take advantage of the normal healing pathways at a greatly accelerated rate. During the healing process, the body rushes many cells and cell-types to the injected area in order to accelerate the healing process. These cells perform many functions, including release of growth factors (GF) into the diseased or arthritic and injured sites.

Much less common causes of neck pain include tumors, infections, or congenital abnormalities of the vertebrae. There is also the emotional part, I mean why would the pain get worse with stress and get better with less stress, this must be emphasized when treating patient with neck pain other wise the job is not done. Why the tingling of the fingers? this is because of nerve conduction and dermatomes. Dermatomes are located on the anterior body and the posterior body and are consecutive in the neck and torso regions. Development of the peripheral nervous system will produce a pattern of skin innervated by cutaneous neurons of a certain spinal or cranial nerves. These are called dermatomes and represent specific regions of nerve reception of sensory impulses. The pattern of the dermatome is of major clinical significance when a physician desires to treat a particular portion of the body. For instance the gentleman discussed in the above case having numbness in the index finger as well as his thumb (refer to the picture) may need to be treated specifically at the level of C6-C7.

U.S.A. based physician, Dr. Farshchian is a medical author, humanitarian, and active republican member. He is best known for coining the term "orthopedic regenerative medicine." Dr. Farshchian is recognized as a leading authority in the new clinical science of regenerative medicine. He is also a Television personality, currently hosting "The Arthritis Show."

The Center for Regenerative Medicine in Miami, Florida concentrates on helping arthritic and injured people to get back to a functional level of life and their activities using non-surgical techniques and Orthopedic medicine. The center's expertise is in treatment of conditions of spine, knees , shoulders , and other cartilage damages. They have developed non-surgical and rehabilitation techniques focused on treatment and management of joint pain. Their team includes health professionals organized around a central theme. their website is http://www.arthritisusa.net

Read this article:
Dr. Farshchian: Autologous Cell therapy is Now Being Used to Help with Neck Pain at The Center for Regenerative Medicine

Recommendation and review posted by Bethany Smith

Autologous cell therapy is now being used to help with avascular necrosis at the Center for Regenerative Medicine, according to Dr. Farshchian.

Miami, Fl (PRWEB) December 10, 2012

Avascular necrosis can be quite devastating, and lead to total loss of the ankle joint with arthritis, deformity and pain. Loss of blood supply to the bone can be caused by an injury (trauma-related avascular necrosis) When a joint is injured, as in a fracture or dislocation, the blood vessels may be damaged. This can interfere with the blood circulation to the bone and lead to trauma-related avascular necrosis. Studies suggest that this type of avascular necrosis may develop in more than 20 percent of people who dislocate their hip joint.

Some medicines such as Corticosteroids are commonly used to treat diseases in which there is inflammation, such as systemic lupus erythematosus, rheumatoid arthritis, and vasculitis. Studies suggest that long-term, systemic (oral or intravenous) corticosteroid use is associated with 1/3 of all cases of non-traumatic avascular necrosis. The current theory is corticosteroids may interfere with the body's ability to break down fatty substances. These substances then build up in and clog the blood vessels, causing them to narrow. This makes less blood to gets to the bone. Excessive alcohol use and corticosteroid use are two of the most common causes of non- traumatic avascular necrosis. In people who drink an excessive amount of alcohol, fatty substances may block blood vessels causing a decreased blood supply to the bones that results in avascular necrosis.

Sports injuries need an adequate blood supply and cellular migration. Platelet-derived growth factors are critically involved in this process. These cells allow the body to take advantage of the normal healing pathways at a greatly accelerated rate. During the healing process, the body rushes many cells and cell-types to the injected area in order to accelerate the healing process. These cells perform many functions, including release of growth factors (GF) into the diseased or arthritic and injured sites.

Other risk factors or conditions associated with non-traumatic avascular necrosis include Gaucher's disease, pancreatitis, radiation treatments and chemotherapy, and blood disorders such as sickle cell disease. Avascular necrosis strikes both men and women and affects people of all ages. It is most common among people in their thirties and forties. Depending on a person's risk factors and whether the underlying cause is trauma, it also can affect younger or older people.

In the early stages of avascular necrosis, patients may not have any symptoms. As the disease progresses, however, most patients experience joint painat first, only when putting weight on the affected joint, and then even when resting. Pain usually develops gradually and may be mild or severe. If avascular necrosis progresses and the bone and surrounding joint surface collapses, pain may develop or increase dramatically. Pain may be severe enough to limit the patient's range of motion in the affected joint. The period of time between the first symptoms and loss of joint function is different for each patient, ranging from several months to more than a year.

U.S.A. based physician, Dr. Farshchian is a medical author, humanitarian, and active republican member. He is best known for coining the term "orthopedic regenerative medicine." Dr. Farshchian is recognized as a leading authority in the new clinical science of regenerative medicine. He is also a Television personality, currently hosting "The Arthritis Show."

The Center for Regenerative Medicine in Miami, Florida concentrates on helping arthritic and injured people to get back to a functional level of life and their activities using non-surgical techniques and Orthopedic medicine. The center's expertise is in treatment of conditions of spine, knees , shoulders , and other cartilage damages. They have developed non-surgical and rehabilitation techniques focused on treatment and management of joint pain. Their team includes health professionals organized around a central theme. their website is http://www.arthritisusa.net

Marty Eugene http://www.arthritisusa.net 305 8668384 Email Information

The rest is here:
Dr. Farshchian: Autologous Cell Therapy is Now Being Used to Help with Avascular Necrosis at The Center for ...

Recommendation and review posted by Bethany Smith

SAN DIEGO, Dec. 10, 2012 (GLOBE NEWSWIRE) -- The Global Institute Of Stem-cell Therapy And Research (GIOSTAR) announced today a collaborative treatment plan to serve the local population suffering from a genetic disease, Sickle Cell Anemia. President and CEO, Mr. Deven Patel and his team met with Honorable Chief Minister Shri Arjun Munda of State of Jharkhand, India in November 2012 to address the local population's medical needs.

A photo accompanying this release is available at http://www.globenewswire.com/newsroom/prs/?pkgid=16184.

As a follow-up, a government delegation representing the state of Jharkhand, India; Chief Minister, Principal Health Secretary, Chief Secretary and many other officials are visiting GIOSTAR in San Diego on December 14, 2012 to finalize the proposed two (2) billion U.S. dollar contract to be serviced over the next 15 years.

Bob Filner, Mayor of San Diego and City Council Members are among the invited guests for this state visit along with representatives from Belize and the island nation of Saint Vincent and the Grenadines.

Two hundred (200) jobs are estimated to be created in San Diego and it is expected that the dialog would include an economic development program between City of San Diego and State of Jharkhand, India.

GIOSTAR is a Global Private Funding (Global) incubated company. "Global is a private equity firm that focuses on funding projects and initiatives that are job-creation centric rather than just profit centric. We believe that a venture that draws the best minds and hearts to a unified goal, driven by a unified vision tends to be far stronger and less prone to failure than one driven by just profit. We invest in people, not the business," said Dr. Sam Senev, Chairman and CEO of Global. Senev added that GIOSTAR is a showcase client focused on both serving mankind through quality of life and job creation.

GIOSTAR, headquartered in San Diego, California (USA), was formed with the vision to provide stem cell based therapy to aid those suffering from degenerative or genetic diseases around the world. We are the leaders in developing innovative stem cell based technology.

The Chairman and Cofounder of GIOSTAR, Dr. Anand Srivastava and our team of scientists and clinicians have been associated with leading universities and research institutions throughout USA. GIOSTAR team has extensive research and clinical experience in the field of Stem cell, which is documented by several publications in revered scientific journals.

GIOSTAR in July 2011, inaugurated the world's first dedicated stem cell treatment hospital, a 125-bed, contemporary facility with the most advanced on-site stem cell laboratory. This hospital is fully operational. GIOSTAR is developing the world's largest, a three hundred thousand square-foot (300,000SF) state-of-the-art, Stem Cell Treatment Hospital in the Surat Civil Hospital Campus in collaboration with the government of Gujarat. Negotiations are ongoing with China, Philippines, Bahamas, Belize, Thailand, Ukraine and the Middle East to open regional stem cell treatment hospitals and satellite clinics throughout those countries and regions. "We are expanding the GIOSTAR footprint and is in negotiations to open locations near Austin Texas, Phoenix Arizona, and Savannah South Carolina" said Michael Andersen, Vice President of Venture Management at Global. Global and Empyrean West, EB-5 administrators, plan to invest over one hundred and eighty million ($180M) in economic development investments for GIOSTAR projects.

The Global Institute of Stem Cell Therapy and Research company logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=16183.

More here:
Photo Release -- GIOSTAR and the Government of India to Enter $2 Billion Stem Cell Therapy Program - Official State ...

Recommendation and review posted by Bethany Smith

LONDON (Reuters) - U.S. biotechnology group Amgen Inc has agreed to buy unlisted Decode Genetics, a pioneer in hunting down genes linked to disease, for $415 million in cash to boost its drive to develop better targeted drugs.

Founded in 1996, Decode blazed a trail in personal genomics by trawling Iceland's unique genetic heritage, which has changed little since the Vikings arrived more than 1,000 years ago, to work out the links between gene variants and common diseases.

But it failed to live up to early expectations after going public in 2000 and filed for bankruptcy protection in 2009, weighed down by debts after 13 years of failing to make a profit, before re-emerging as a privately owned company.

Amgen and Decode said on Monday that the transaction did not require regulatory approval and was expected to close before the end of 2012.

As part of Amgen, Decode's scientists will help in the task of ensuring that experimental medicines hit the right spot. Their know-how should allow Amgen to identify promising new avenues earlier and close down dead-ends more quickly.

"This fits perfectly with our objective to pursue rapid development of relevant molecules that reach the right disease targets, while avoiding investments in programs based on less well-validated targets," Amgen Chief Executive Robert Bradway said.

PERSONALISED MEDICINE

UBS analysts said that the purchase, which will be funded by cash held offshore, was not surprising given that Amgen has key experimental drugs in its pipeline that were identified by human genetics work, including AMG 145 for heart disease and the bone drug romosozumab.

Understanding the genetic basis of disease has become increasingly important in drug discovery as the pharmaceutical industry shifts to developing personalized medicine that is suited for a patient's particular genetic profile.

It is an area where Decode has extensive experience and its scientists have published prolifically on genetic mutations linked to a range of diseases including cancer, heart conditions and schizophrenia.

More:
Amgen buys Icelandic gene hunter Decode for $415 million

Recommendation and review posted by Bethany Smith

1. Introduction and Overview- Biotechnology: Panacea or Pandora #39;s Box NQ
Given the rapid recent advances in genomics, agriculture, transgenic biology, stem cell research and other related areas of biotechnology and a prediction that these fields will continue to mature and become increasingly more sophisticated, there is an growing need to create an informed and educated student in this area. We believe that a working knowledge of DNA, genetics, and biotechnology has become as fundamental to a basic education as an understanding of the solar system. In addition, biotechnology fields offer students career opportunities which is best recognized early in their academics so that they can make the appropriate choices to be best prepared. The rise of recent controversy and misconceptions about many areas of biotechnology including GMOs in food, vaccines and vaccination, personalized medicine, stem cell research and many other topics creates a growing educational challenge. The introduction of a general education course which concentrates on evidence based knowledge on biotechnology and is developed for a general audience with a large potential enrollment is designed to meet that challenge. In turn our experience shows that such a course serves to recruit new scientists and other participants into the careers in the emerging new fields of biotechnology and stimulates further interest in STEM related disciplines. The courses in this series have been established in the curriculum over the past several years with high student demand and interest. Given ...From:Albert KauschViews:0 0ratingsTime:01:05:12More inScience Technology

Excerpt from:
1. Introduction and Overview- Biotechnology: Panacea or Pandora's Box NQ - Video

Recommendation and review posted by Bethany Smith

Genetic Engineering Awareness
From:corinne ramosViews:2 0ratingsTime:03:50More inPeople Blogs

Read this article:
Genetic Engineering Awareness - Video

Recommendation and review posted by Bethany Smith

Ramble: Simelweis Taboo
I just don #39;t understand narrowmindedness. I don #39;t understand the stubborn refusal to face reality with integrity. I don #39;t understand cowardice. We each have only one life. Why squander it on timidity, prejudice and just so stories? Video referenced: "Taboos of Science" scishow youtu.be " Published on Jul 30, 2012 Hank discusses some of the taboos which have plagued scientific inquiry in the past and a few that still exist today. Like SciShow? http://www.facebook.com Follow SciShow: http://www.twitter.com References: dft.ba This video contains the following sounds from Freesound.org: "grim fart.wav" by Walter_Odington "Toilet Flush.wav" by tweeterdj science, scishow, taboo, society, culture, research, study, ignaz semmelweis, germ theory, disease, louis pasteur, antiseptic, social norms, semmelweis reflex, dean radin, noetic science, stem cell, chimaera, human cloning, clone, dolly, sheep, ethics, religion, panayiotis zavos, synthetic biology, genetic engineering, biology, genetics, mental health, gender identity, gender dysphoria, sexual orientation, physics, archaeology, human remains, spirituality, consciousness, poop, toilet, sanitation"From:rriverstone1Views:20 2ratingsTime:15:28More inPeople Blogs

See the original post here:
Ramble: Simelweis Taboo - Video

Recommendation and review posted by Bethany Smith

GEARS - Genetic Engineering at Rutgers Society
Biology Undergraduates discuss their research projects, their findings, and experiences conducting research at Rutgers.From:RutgersViews:7 0ratingsTime:06:34More inEducation

The rest is here:
GEARS - Genetic Engineering at Rutgers Society - Video

Recommendation and review posted by Bethany Smith

Washington, December 10 (ANI): A new study has suggested that just as human DNA varies from person to person, so too does the massive collection of microbial DNA in the intestine.

The research was conducted by researchers at Washington University School of Medicine in St. Louis and the European Molecular Biology Laboratory in Heidelberg, Germany.

It is the first to catalog the genetic variation of microbes that live in the gut, where they extract nutrients from food, synthesize vitamins, protect against infections, and produce compounds that naturally reduce inflammation.

The widespread genetic diversity uncovered by the scientists can help them understand how our microbial genes work together with our human genes to keep us healthy or, in some cases, to cause disease.

"Surprisingly, each of us can be identified by the collective DNA of our gut microbes," said corresponding author George Weinstock, PhD, associate director of The Genome Institute at Washington University.

"That collection is individualized, completely analogous to our human genome. Differences in the way individuals respond to various drugs or the way they use specific nutrients can be traced to the genetic variation in our microbial genes as well as in our human genes," he stated.

The researchers analyzed the microbial DNA in 252 stool samples from 207 individuals living in the United States and Europe.

All the subjects had participated in one of two recent high-profile initiatives to catalog the diverse species of microbes that live in and on the body. Neither of those studies - the Human Microbiome Project, funded by the National Institutes of Health, and the Metagenomics of the Human Intestinal Tract (MetaHIT) project, funded by the European Commission - looked at the genetic variation of the microbial genomes in the body.

For the new study, the researchers zeroed in on 101 species of microbes commonly found in the intestine, identifying more than 10 million single-letter changes in the collective DNA of those microbes. They also found numerous other DNA alterations, including insertions, deletions and structural changes.

In 43 subjects for whom the researchers had two stool samples collected at least a month apart (most were collected six months to a year after the initial sample), the researchers found very little variability in the microbial DNA over time, although the species of microbes in the intestine fluctuated.

View post:
Gut microbes identified as new genetic fingerprint

Recommendation and review posted by Bethany Smith

MELVILLE, N.Y.--(BUSINESS WIRE)--

Population Diagnostics, Inc. (PDx), a private company with a novel approach for systematically uncovering the genetic causes of disease as well as the genetic basis of drug efficacy and safety, together with collaborators from The Hospital for Sick Children (SickKids) in Toronto, reported today in the journal G3 (GenesGenomesGenetics) the discovery of a collection of gene variants for autism spectrum disorder. These variants confer clinical utility and will enable a new generation of early detection diagnostic tests that will be highly sought after by the patient community. The newly discovered variants will also provide insights into the emerging field of drug discovery for autism.

Our collaboration with Population Diagnostics has been very fruitful, said the primary investigator, Dr. Stephen Scherer at The Hospital for Sick Children. We set out to understand microarray platform differences in copy number variant (CNV) detection but because of PDxs technical contribution, which delineates benign variants from those that are pathogenic, we were able to effectively interpret the genome at a higher resolution than obtained with previously utilized microarrays. This focused our attention on smaller variants associated with autism. Not only were we able to confirm variants in genes that we and others have previously discovered using alternate methods, but more importantly, we are pleased that an abundance of novel variants have been uncovered. We intend to report on additional discoveries in future publications that are based on an even finer-scale interpretation of the data in this joint project.

In addition to discovering sixteen novel genes associated with autism (many implicated in neurodevelopment), this study highlights the general importance of analyzing genomes specifically for CNVs, which is a type of genetic variant that can disrupt, delete, or generate multiple copies of a gene. However, the analytical tools that detect CNVs differ significantly in their output. For example, 64% of the CNVs observed in this study using a high resolution platform specifically designed to detect CNVs were missed in a prior CNV study that used SNP microarrays, which are not optimized for CNV detection because they were originally designed to detect another class of variants called single nucleotide polymorphisms (SNPs). Many SNP-based studies did not yield sufficient medically useful information and the SNP microarray data were subsequently mined for the presence of CNVs, which is a suboptimal strategy. The size of CNVs that can be detected is a key difference, and in this study the researchers found that 75% of the CNVs missed by SNP microarrays were small and these afford a greater opportunity to pinpoint single genes involved in autism. A more refined analysis of the autism patients used in the present study is underway and is revealing additional small CNVs in novel autism genes as well as novel variants in previously known autism genes.

Population Diagnostics holds two US patents (7,702,468 and 7,957,913) that describe a method of comparison of CNVs in subjects with a given condition to those present in a cohort comprised of healthy individuals. By eliminating benign and irrelevant CNVs in such a comparison, one is quickly led to genes that are pathogenic, which can then be interrogated using higher resolution genetic analysis techniques such as sequencing. In addition to disease gene discovery, PDxs methods can also reveal genetic biomarkers applicable for patient stratification (optimization of clinical trials), such as genetically differentiating a drug responder from a non-responder (efficacy) or identifying individuals most likely to experience a serious adverse event to a given drug.

The discoveries reported in this study underscore that the genetic landscape for autism involves numerous genes containing many low frequency genetic variants with large effect, said Dr. Peggy Eis, Chief Technology Officer at Population Diagnostics. Collectively, these newly discovered genes from our collaboration with SickKids, along with novel genes from our finer-scale analysis that will be reported in a future paper, represent a significant portion of the unexplained genetic contribution to autism and greatly expand our understanding of the underlying genetic causes of autism. We are excited about the opportunity to accelerate their clinical use in diagnostic tests, as potential drug targets and as genetic biomarkers in therapeutics development.

The US CDC estimates 1 in 88 children have autism. Genetics is believed to be the major causal factor, with up to 90% of cases having a genetic contribution. Rare gene variants are usually sufficient to cause autism by themselves. There is no single cause or type of autism. The average age of diagnosis is 4.5 years via observational methods and it is clear that the earlier the diagnosis the better the treatment outcome through early intervention modalities. With knowledge of the various genetic causes, a genetic test can be performed immediately after the birth of a child and provide the maximum opportunity for treatment. There are ~4 million live births in the US per year and 45,000 of these newborns will develop autism.

About Population Diagnostics, Inc.

Population Diagnostics, Inc. (PDx, http://www.populationdiagnostics.com) is applying its discoveries in human genetics to the development of DNA-based diagnostics and personalized medicine tests. PDxs technology, which reveals the genetic causes of complex diseases such as autism, Parkinsons, Alzheimers, and food allergies, enables development of early detection diagnostic tests that predict pre-symptomatically why some individuals will suffer from debilitating diseases while others will not. When applied to drug discovery, the technology enables pharmaceutical companies to develop targeted therapies and companion diagnostics. Its novel technology and exclusive products places PDx in a prime position to (i) transform how physicians diagnose and manage disease in their patients and (ii) enable pharmaceutical companies to expand the number of available therapies and market drugs with higher efficacy and safety.

The rest is here:
Population Diagnostics, Inc. and The Hospital for Sick Children Discover Novel Genetic Variants Associated with Autism ...

Recommendation and review posted by Bethany Smith

Being a little bit Godly - The Hidden
Just playing a bit of the Hidden What the hell is going on you ask? Storyline In the early 1950s human genetics experimentation was taking its first, tentative steps. Amongst many other black projects, a team of British scientists working at an Infinitum Research experimental station stumbled across some remarkable phenomena involving DNA manipulation. This led to deeper research with dangerously unpredictable results, often leading to human patients losing their lives in irresponsible and immoral experiments. Time passed on, and by the mid 1990s the failure rate of the experiments had been reduced from 75% to a mere 15%, enough for Infinitum to move onto the next stage: Biological Light Refraction. The British team were hoping to unravel the possibilities of light manipulation to create the perfect covert military agent. Early into the new millennium, due to a gross miscalculation, a series of tests on Subject 617 led to a massive synaptic trauma leaving the patient with multiple genetic anomalies. The subject was left in constant pain and with unstable DNA. The subject escaped captivity, killing anyone that got in its way. The IRIS (Infinitum Research Interception Squad) team have been deployed to return the subject to a maximum security Infinitum Research facility for further study and dissection. The entire project was considered a failure: all funding ceased and development was discontinued while all records and traces of the experiments were destroyed. Infinitum ...From:MultiAwesomeness96Views:4 1ratingsTime:04:44More inGaming

See the original post:
Being a little bit Godly - The Hidden - Video

Recommendation and review posted by Bethany Smith

Genetics Project : Traits
Like . Comment . Subscribe **No copyright intended**From:xxXPANDAliciousXxxViews:2 1ratingsTime:03:11More inMusic

Read the original post:
Genetics Project : Traits - Video

Recommendation and review posted by Bethany Smith

Genetics Review UCO Fall 2012 Part 1
From:minabonita100Views:2 0ratingsTime:01:00:01More inScience Technology

Read more:
Genetics Review UCO Fall 2012 Part 1 - Video

Recommendation and review posted by Bethany Smith

Archive Genetics Pt. 6
Day 54 of FlowerFrom:GODLUNGSViews:132 24ratingsTime:04:01More inEntertainment

Read the rest here:
Archive Genetics Pt. 6 - Video

Recommendation and review posted by Bethany Smith

Genetics Review UCO Fall 2012 Part 2
From:minabonita100Views:0 0ratingsTime:38:22More inScience Technology

Go here to read the rest:
Genetics Review UCO Fall 2012 Part 2 - Video

Recommendation and review posted by Bethany Smith

Bone marrow transplants: Genetics linked to heart failure after chemotherapy | City of Hope Research
Saro Armenian, DO, MPH, medical director, Pediatric Survivorship Clinic at City of Hope discusses his recent study demonstrating that genetics may explain why some bone marrow transplant survivors develop congestive heart failure after receiving chemotherapy called anthracyclines. The findings will enable physicians to better screen at-risk patients and potentially prevent this lethal complication. ###################### Learn more about Saro Armenian, DO, MPH - http://www.cityofhope.org CONNECT WITH CITY OF HOPE http://www.facebook.com http://www.twitter.com http://www.causes.com and more at http://www.cityofhope.org ABOUT CITY OF HOPE City of Hope is a leading medical research, treatment and education center dedicated to preventing, treating and curing cancer, diabetes, HIV/AIDS and other life-threatening diseases. Our mission is to quickly turn research ideas into cures that help save patients #39; lives all over the world. Learn more at http://www.cityofhope.org.From:cityofhopeonlineViews:12 0ratingsTime:02:00More inEducation

Continued here:
Bone marrow transplants: Genetics linked to heart failure after chemotherapy | City of Hope Research - Video

Recommendation and review posted by Bethany Smith

Amgen Purchases Company in Iceland
The biotech manufacturer, which has a facility in West Greenwich, has agreed to buy Decode Genetics, a gen-hunting company in Iceland.From:WPRIViews:0 0ratingsTime:00:25More inNews Politics

View post:
Amgen Purchases Company in Iceland - Video

Recommendation and review posted by Bethany Smith

Max Cooper feat. Braids - Automaton (D/R/U/G/S Mxcpr Remix)
Conditions One EP loz; Fields #887396917491 loz; Released:10.12.2012 soundcloud.com braidsmusic.com soundcloud.com http://www.beatport.com Buy it: http://www.beatport.com Release Info: Rising UK electronica star Max Cooper has collaborated with Canada?s intellectual art-rockers BRAIDS on a two-part EP named CONDITIONS ONE. The human condition is a well-examined idea ? but as an ex-genetics researcher with a PhD, Cooper takes a somewhat aslant look at humanity with the two collaborations. ?Pleasures,? he says, ?is just that ? an attempt to write something purely pleasurable and beautiful. But Automaton is darker ? an attempt to show how humans are essentially deterministic, trapped in a set of predictable reactions to their environment, their upbringing, their lives?. All three members of BRAIDS sing, and the tracks on the CONDITIONS EP combine vocal lines, melodies and individual vocal sounds from every song on BRAIDS? most recent album, Native Speaker ? both as ?proper vocals?, and or ethereal, pure sound.From:SteepedInMystery1Views:0 0ratingsTime:06:38More inMusic

Read more:
Max Cooper feat. Braids - Automaton (D/R/U/G/S Mxcpr Remix) - Video

Recommendation and review posted by Bethany Smith

TRENTON, N.J. (AP) Biotech pioneer Amgen Inc., in a bid for a big edge in using people's genetic information to find better ways to attack diseases, is buying human genetics research and analytics leader deCODE Genetics for $415 million.

Amgen, the world's largest biotech company by revenue, and deCODE, based in Reykjavik, Iceland, announced the all-cash deal Monday.

DeCODE, founded in 1996, has discovered genetic risk factors for dozens of diseases, ranging from cardiovascular disease to cancer.

Probably its key asset and the reason for the deal is deCODE's huge database of the genetic and medical information of Iceland's population. That data can help researchers find links between genetic variations and characteristics that increase a person's risk of getting a particular disease and also affect patients' response to a drug.

"DeCODE Genetics has built a world-class capability in the study of the genetics of human disease. This capability will enhance our efforts to identify and validate human disease targets," Amgen CEO Robert Bradway said in a statement.

"This fits perfectly with our objective to pursue rapid development of relevant molecules that reach the right disease targets while avoiding investments in programs based on less well-validated targets," Bradway added.

That's important because the vast majority of experimental drugs, after years of expensive testing, eventually turn out not to work well or to have dangerous side effects. Drugmakers worldwide are trying to find ways to make their drug-development process more efficient to avoid spending tens of millions of dollars testing drugs that end up failing.

UBS Securities analyst Matthew Roden wrote in a note to investors that Amgen management stressed to him that being able to more efficiently identify and confirm targets for future development would help the company spot promising candidates, as well as likely failures, earlier.

"It is not surprising that Amgen is building out this R&D capability," given that some of its key experimental drugs were identified based on human genetics work, Roden wrote.

He has a "Buy" rating for Amgen and a 12-month share price target of $96, higher than its shares have ever been and significantly above its $89.95 peak over the last year. Roden noted Amgen will use off-shore cash for the deal and will not issue debt to cover it.

Original post:
Amgen buying deCODE Genetics for $415 million

Recommendation and review posted by Bethany Smith

ATLANTA--(BUSINESS WIRE)--

Seattle Genetics, Inc. (SGEN) today summarized ADCETRIS (brentuximab vedotin) data in relapsed Hodgkin lymphoma (HL) and other CD30-positive malignancies from multiple presentations at the 54th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 8-11, 2012 in Atlanta, GA. Highlights include compelling survival data from long-term follow up in a pivotal clinical trial of ADCETRIS in relapsed or refractory HL and a retrospective comparison of overall survival among patients treated with ADCETRIS to those not treated with ADCETRIS following an autologous stem cell transplant (ASCT). In addition, data describe the activity and tolerability of ADCETRIS in the salvage HL setting from an investigator-sponsored trial and in relapsed patients age 60 or over with CD30-positive malignancies, including HL. ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, a defining marker of classical HL.

"There are more than a dozen data presentations at ASH evaluating the use of ADCETRIS in CD30-positive malignancies and we are very encouraged by both the broad application across multiple hematologic disease areas as well as the encouraging activity associated with ADCETRIS, said Clay B. Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics. The extensive investigator and corporate data presentations at ASH clearly demonstrate the important role ADCETRIS plays in the treatment of relapsed HL and systemic anaplastic large cell lymphoma and the promise of the role it potentially will play in additional future indications.

Long-term Survival Analysis of an Ongoing Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Hodgkin Lymphoma (Abstract #3689)

A pivotal, single-arm trial was conducted in 102 relapsed or refractory HL patients after ASCT to assess efficacy and safety of single-agent ADCETRIS. In addition, the trial was designed to determine duration of response, progression-free survival and overall survival. Enrolled patients had received a median of more than three prior chemotherapy regimens.

Data highlights from the long-term survival analysis in the pivotal trial were:

Overall Survival Benefit for Patients with Relapsed Hodgkin Lymphoma Treated with Brentuximab Vedotin After Autologous Stem Cell Transplant (Abstract #3701)

An independent retrospective comparison conducted by MD Anderson Cancer Center evaluated overall survival in 102 relapsed HL patients treated with ADCETRIS in a pivotal clinical trial compared to data from 756 relapsed HL patients treated at six international centers (Horning et al., 2008). The authors compared median overall survival, starting at the time of receiving an ASCT, among ADCETRIS treated patients to patients not treated with ADCETRIS. Key findings, which were highlighted in a presentation by Dr. Meghan Karuturi from MD Anderson Cancer Center, included:

Brentuximab Vedotin as a First Line Salvage Therapy in Relapsed/Refractory HL (Abstract #3699)

An investigator-sponsored trial was conducted to evaluate ADCETRIS as a salvage therapy for HL. Fourteen patients were evaluated for response and safety and all had relapsed or refractory HL after initial therapy with the chemotherapy regimens ABVD (Adriamycin, bleomycin, vinblastine, dacarbazine) or BEACOPP (bleomycin, etoposide, Adriamycin, cyclophosphamide, Oncovin, procarbazine hydrochloride, prednisone) or a combination of chemotherapy with or without consolidative radiation treatment. Patients were treated with ADCETRIS every three weeks for a maximum of four cycles. Data were presented by Dr. Robert Chen from City of Hope National Medical Center in Duarte, CA.

Read the original:
Seattle Genetics Highlights ADCETRIS® (Brentuximab Vedotin) Data in Relapsed Hodgkin Lymphoma and Other CD30-Positive ...

Recommendation and review posted by Bethany Smith

ATLANTA--(BUSINESS WIRE)--

Seattle Genetics, Inc. (SGEN) today presented preclinical data from SGN-CD33A, an antibody-drug conjugate (ADC) in development for the treatment of acute myeloid leukemia (AML), at the 54th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 8-11, 2012 in Atlanta, GA. SGN-CD33A is a novel CD33-directed ADC utilizing Seattle Genetics next generation technology. The CD33 antibody is attached to a highly potent cytotoxic agent called a pyrrolobenzodiazepine (PBD) dimer via a proprietary site-specific conjugate technology to a monoclonal antibody with engineered cysteines (EC-mAb). Seattle Genetics expects to advance SGN-CD33A into a phase I clinical trial in 2013.

Our SGN-CD33A program showcases our next generation ADC technology, including our latest highly potent cell-killing agent and our new engineered antibody technology, said Jonathan Drachman, M.D., Senior Vice President, Research and Translational Medicine at Seattle Genetics. Of approximately 30 ADCs in development, more than 50 percent utilize Seattle Genetics technology. Through our continued innovation we are leading the development of novel ADCs, and believe that ADCs can transform the way cancer is treated.

ADCs are monoclonal antibodies that are designed to selectively deliver cytotoxic agents to tumor cells. This approach is intended to spare non-targeted cells and thus reduce many of the toxic effects of traditional chemotherapy while enhancing antitumor activity.

PBDs are a class of DNA-crosslinking agents that are significantly more potent than systemic chemotherapeutic drugs. Seattle Genetics has been working with PBDs since 2008 under an exclusive licensing arrangement with Spirogen Ltd. Over the past four years, Seattle Genetics has selected and optimized specific PBD molecules combined with novel linkers for use in ADCs, and has conducted process development and scale-up activities to create robust synthetic GMP manufacturing processes for these PBD drug-linkers.

SGN-CD33A: A Novel CD33-Directed Antibody-Drug Conjugate, Utilizing Pyrrolobenzodiazepine Dimers, Demonstrates Preclinical Antitumor Activity Against Multi-Drug Resistant Human AML (Abstract #3589)

Key findings from the preclinical evaluation of SGN-CD33A included:

About Seattle Genetics

Seattle Genetics is a biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer. The U.S. Food and Drug Administration granted accelerated approval of ADCETRIS in August 2011 for two indications. ADCETRIS is being developed in collaboration with Millennium: The Takeda Oncology Company. In addition, Seattle Genetics has three other clinical-stage ADC programs: SGN-75, ASG-5ME and ASG-22ME. Seattle Genetics has collaborations for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including Abbott, Agensys (an affiliate of Astellas), Bayer, Celldex Therapeutics, Daiichi Sankyo, Genentech, GlaxoSmithKline, Millennium, Pfizer and Progenics, as well as ADC co-development agreements with Agensys and Genmab. More information can be found at http://www.seattlegenetics.com.

Certain of the statements made in this press release are forward looking, such as those, among others, relating to the initiation of future clinical trials with SGN-CD33A. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the inability to generate the appropriate data and information to support an investigational new drug submission to the FDA. More information about the risks and uncertainties faced by Seattle Genetics is contained in the companys 10-Q for the quarter ended September 30, 2012 filed with the Securities and Exchange Commission. Seattle Genetics disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Read more:
Seattle Genetics Highlights Next Generation Antibody-Drug Conjugate SGN-CD33A at ASH Annual Meeting

Recommendation and review posted by Bethany Smith

ATLANTA--(BUSINESS WIRE)--

Seattle Genetics, Inc. (SGEN) today announced that results from two ongoing investigator-sponsored phase II clinical trials of ADCETRIS (brentuximab vedotin) in patients with relapsed cutaneous T-cell lymphoma (CTCL) were presented at the 54th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 8-11, 2012 in Atlanta, GA. ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30. ADCETRIS has not been approved for use in the treatment of CTCL.

Brentuximab Vedotin Demonstrates Significant Clinical Activity in Relapsed or Refractory Mycosis Fungoides with Variable CD30 Expression (Abstract #797)

The ongoing phase II clinical trial is enrolling CTCL patients with mycosis fungoides (MF) or Sezary syndrome. Twenty patients have been enrolled to date with a median of six prior systemic therapies. The primary endpoint of the trial is clinical response rate. Secondary endpoints include correlation of clinical response with CD30 expression levels, duration of response and safety. The study was led by principle investigator Dr. Youn H. Kim from Stanford University School of Medicine in Stanford, CA, and was presented in an oral session. Key findings include:

Results of a Phase II Trial of Brentuximab Vedotin (SGN-35) for CD30+ Cutaneous T-Cell Lymphomas and Lymphoproliferative Disorders (Abstract #3688)

Data were presented from a phase II investigator-sponsored trial evaluating the use of ADCETRIS in CD30-positive CTCL patients, including lymphomatoid papulosis (LyP), primary cutaneous anaplastic large cell lymphoma (pcALCL) or MF. The ongoing study is being conducted by Dr. Madeleine Duvic from The University of Texas MD Anderson Cancer Center in Houston, TX. Among 54 patients enrolled to date, 46 patients were evaluable at the time of analysis. The primary endpoint of the trial is to evaluate the safety and efficacy of ADCETRIS in CD30-positive CTCL. The key findings include:

Seattle Genetics and Millennium: The Takeda Oncology Company have initiated the ALCANZA trial, a randomized phase III clinical trial of ADCETRIS for relapsed CD30-positive CTCL patients. The trial is assessing ADCETRIS versus investigators choice of methotrexate or bexarotene in patients with CD30-positive CTCL, including those with pcALCL or MF. The primary endpoint of the study is overall response rate lasting at least four months. Approximately 124 patients will be enrolled in the pivotal trial. The ALCANZA trial is being conducted under a Special Protocol Assessment agreement from the U.S. Food and Drug Administration (FDA). The study also received European Medicines Agency scientific advice.

About CTCL

Lymphoma is a general term for a group of cancers that originate in the lymphatic system. There are two major categories of lymphoma: Hodgkin lymphoma and non-Hodgkin lymphoma. Cutaneous lymphomas are a category of non-Hodgkin lymphomas that primarily involve the skin. According to the Cutaneous Lymphoma Foundation, CTCL is the most common type of cutaneous lymphoma and typically presents with red, scaly patches or thickened plaques of skin that often mimic eczema or chronic dermatitis. Progression from limited skin involvement is variable and may be accompanied by tumor formation, ulceration and exfoliation, complicated by itching and infections. Advanced stages are defined by involvement of lymph nodes, peripheral blood and internal organs. According to published literature, up to 50 percent of CTCL patients lesions express CD30.

About ADCETRIS

Excerpt from:
Seattle Genetics Announces Data from Investigator-Sponsored Trials of ADCETRIS® (Brentuximab Vedotin) in Cutaneous T ...

Recommendation and review posted by Bethany Smith

ATLANTA--(BUSINESS WIRE)--

Seattle Genetics, Inc. (SGEN) today announced results from a phase I clinical trial of ADCETRIS (brentuximab vedotin) in combination with chemotherapy for the treatment of newly diagnosed advanced stage Hodgkin lymphoma (HL) patients. The data were presented at the 54th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 8-11, 2012 in Atlanta, GA. ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, a defining marker of classical HL. ADCETRIS is currently not approved for use in the front-line treatment of HL.

In the phase I trial, newly diagnosed patients received ADCETRIS concomitantly with either ABVD (Adriamycin, bleomycin, vinblastine and dacarbazine) or AVD, which removes bleomycin from the regimen. At the end of front-line therapy, 24 of 25 patients (96 percent) treated with ADCETRIS plus AVD and 21 of 22 (95 percent) patients treated with ADCETRIS plus ABVD had a complete remission. None of the patients treated in the ADCETRIS plus AVD cohort experienced pulmonary toxicity, compared with an expected rate of pulmonary toxicity caused by ABVD alone of 10-25 percent. The trial was designed to establish the safety profile and maximum tolerated dose when adding ADCETRIS to ABVD or AVD. Antitumor activity was assessed as a secondary endpoint.

"For over 30 years, the standard of care for front-line HL has been a chemotherapy regimen called ABVD that has demonstrated a complete remission rate of 70 to 80 percent and is associated with considerable life-threatening toxicities. There is a significant need to identify better treatment options for patients in the front-line HL setting, said Clay B. Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics. "Our goal is to redefine front-line treatment of HL with the addition of ADCETRIS, and the encouraging results of this phase I trial clearly support this goal and provide rationale for the ongoing ADCETRIS phase III trial in this setting."

Front-line Therapy with Brentuximab Vedotin Combined with ABVD or AVD in Patients with Newly Diagnosed Advanced Stage Hodgkin Lymphoma (Abstract #798)

In this open-label, multicenter trial, cohorts of patients received an escalating dose of ADCETRIS (0.6 milligrams per kilogram (mg/kg), 0.9 mg/kg, 1.2 mg/kg) every two weeks concomitantly with ABVD or a dose of 1.2 mg/kg every two weeks concomitantly with AVD.

Fifty-one patients were enrolled in the phase I study and 47 were evaluable for response at trial completion. The 47 evaluable patients included 25 in the ADCETRIS plus AVD cohort and 22 in the ADCETRIS plus ABVD cohorts. All patients were previously untreated and 45 percent had Stage IV HL. The median age of patients across all cohorts of the trial was 33 years. Key findings, which were highlighted in an oral presentation by Dr. Stephen Ansell, Professor of Medicine, Division of Hematology, from the Mayo Clinic, included:

For decades researchers have strived to improve our front-line HL treatment strategy by enhancing the activity of traditional chemotherapy regimens while reducing the significant toxicities and long-term side effects of such regimens, said Stephen Ansell,M.D., Ph.D., Professor of Medicine, Division of Hematology, Mayo Clinic. There is a significant need to identify better treatment options for patients in the front-line setting. With a complete response rate of 96 percent and a manageable safety profile, data from this trial support further evaluation of ADCETRIS administered concomitantly with AVD in previously untreated HL patients to potentially improve the current standard of care.

Seattle Genetics and Millennium: The Takeda Oncology Company have initiated a phase III clinical trial in advanced stage front-line HL patients. The randomized trial is comparing progression-free survival in patients receiving ADCETRIS in combination with AVD to patients receiving ABVD alone. For more information about the trial visit http://www.seattlegenetics.com or http://www.clinicaltrials.gov.

About ADCETRIS

See the rest here:
Seattle Genetics Reports Data from Phase I Trial of ADCETRIS® (Brentuximab Vedotin) in Front-line Hodgkin Lymphoma at ...

Recommendation and review posted by Bethany Smith